Authors


Jerry McKee, PharmD, BCPP

Latest:

The Value of Board-Certified Psychiatric Pharmacists

Being recognized as a BCPP brings professional recognition and credibility as an expert in psychopharmacology and behavioral health matters.


Portia N. Davis, PharmD

Latest:

Pediatric Asthma: An Update for Pharmacists

In this month's peer-reviewed article, learn more about the illness affecting millions.


Abreah Ash

Latest:

Pediatric Asthma: An Update for Pharmacists

In this month's peer-reviewed article, learn more about the illness affecting millions.


Blanca Guerra, PharmD

Latest:

Pediatric Asthma: An Update for Pharmacists

In this month's peer-reviewed article, learn more about the illness affecting millions.



Jeffrey P. Bratberg, PharmD, BCPS

Latest:

The Regimen: Portrayal of Pharmacists in Media

Jeffrey Bratberg, PharmD and Madi Hartling, a 2025 PharmD candidate, discuss the lack of pharmacists in medical shows and how pharmacists are typically portrayed negatively in media.


Lucinda L. Maine, RPh, PhD

Latest:

Pharmacy Education: Foundation for Providing Health

AACP offers a rebuttal to a Drug Topics opinion article.



Kenneth Maxik

Latest:

3 compliance rules pharmacies must know

With 2016 well underway, pharmacies of all sizes should review recent regulatory updates to ensure compliance with rules already in effect, and preparation for those to be implemented soon. Three, in particular, warrant a close look.


Keith Loria

Latest:

Natural Disasters Pose Risk to Heart Health

The primary challenges include disruption in medication supply and increased demand for essential medications due to heightened health concerns.


Daniel S. Raccuia, PharmD candidate 2016

Latest:

FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting

Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.



Lisa M. Holle, PharmD, BCOP, FHOPA

Latest:

Why You Should Become Board Certified in Oncology

New developments in cancer treatment require medication experts-here's how you can become that expert.



Erin Johanek, PharmD

Latest:

NASH Drug Pipeline Shows Promise

Analysts have forecasted the market for NASH drugs could reach $20 billion by 2025.


Bert Drachtman, BS, RPh

Latest:

Three tips for new pharmacy graduates

Retired pharmacist offers valuable suggestions


Bob Kronemyer

Latest:

OTC Progestin-Only Pill May Prevent Unintended Pregnancies

An over-the-counter (OTC) progestin only pill (POP) could potentially reduce the overall number of unintended pregnancies in the United States.


Adam S. Whalley, PharmD

Latest:

Safinamide (Xadago): Approved as Add-On for Parkinson’s

Xadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.


Andrew Gentry, PharmD

Latest:

Ocrelizumab for Multiple Sclerosis

The FDA has approved ocrelizumab for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.


Partner Perspectives Sponsored by the Arete Pharmacy Network and iMedicare

Latest:

Utilizing a PSAO's Strategic Alliance for Success During Open Enrollment

A high performing Pharmacy Services Administrative Organization (PSAO) actualizes its value proposition to its participating pharmacies by entering into viable strategic partnerships that add value to an independent pharmacy’s workflow processes.


Hannah Buckler, PharmD candidate

Latest:

Ixazomib for multiple myeloma

FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone


Oumaima Sahbani, PharmD

Latest:

Delafloxacin (Baxdela) for Acute Bacterial Skin Infections

Delafloxacin (Baxdela) for treatment of acute bacterial skin and skin structure infections including cellulitis, wound infection, major cutaneous abscess, and burn infection.


Joseph E. Cruz, Pharm.D., BCPS

Latest:

Cardiac Matters

Cangrealor is the first FDA-approved P2Y12 inhibitor.


Germin Fahim

Latest:

New combo therapy for chronic heart failure

Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.



Germin Fahim, PharmD., BCPS

Latest:

Targeting LDL via PCSK-9 from a Different Pathway

A drug underdevelopment may provide another pathway to lowering LDL levels.


Mark Jacobs, RPH, FASCP

Latest:

The future of community pharmacy

Yes, it has one. Here's how to make it real.



Julie Simcik Prince, PharmD, BCPS

Latest:

When IV acetaminophen costs skyrocketed, one health system did some new math

A community hospital study found that a procedural change could save some big bucks.


Danton Dungy, MD

Latest:

When IV acetaminophen costs skyrocketed, one health system did some new math

A community hospital study found that a procedural change could save some big bucks.

© 2025 MJH Life Sciences

All rights reserved.